Total Payments
$359,594
2024 Payments
$35,890
Companies
34
Transactions
1,035
Medicare Patients
3,486
Medicare Billing
$5.1M
Payment Breakdown by Category
Other$297,010 (82.6%)
Travel$23,211 (6.5%)
Food & Beverage$20,059 (5.6%)
Consulting$14,485 (4.0%)
Research$4,574 (1.3%)
Education$253.84 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $182,534 | 104 | 50.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $114,476 | 80 | 31.8% |
| Travel and Lodging | $23,211 | 115 | 6.5% |
| Food and Beverage | $20,059 | 683 | 5.6% |
| Consulting Fee | $14,485 | 13 | 4.0% |
| Unspecified | $4,574 | 18 | 1.3% |
| Education | $253.84 | 22 | 0.1% |
Payments by Type
General
$355,019
1,017 transactions
Research
$4,574
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $167,074 | 248 | $0 (2023) |
| UCB, Inc. | $62,014 | 127 | $0 (2024) |
| Horizon Pharma plc | $35,153 | 62 | $0 (2018) |
| Janssen Biotech, Inc. | $35,045 | 153 | $0 (2024) |
| ABBVIE INC. | $19,165 | 93 | $0 (2024) |
| GlaxoSmithKline, LLC. | $13,421 | 50 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $6,561 | 45 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $6,318 | 17 | $0 (2023) |
| Amgen Inc. | $5,347 | 73 | $0 (2024) |
| Caption Health, Inc. | $2,400 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,890 | 93 | Janssen Biotech, Inc. ($12,976) |
| 2023 | $69,339 | 123 | Horizon Therapeutics plc ($23,290) |
| 2022 | $63,498 | 154 | Horizon Therapeutics plc ($40,478) |
| 2021 | $69,032 | 168 | Horizon Therapeutics plc ($62,239) |
| 2020 | $30,504 | 100 | UCB, Inc. ($17,209) |
| 2019 | $42,108 | 155 | Horizon Therapeutics plc ($30,529) |
| 2018 | $30,436 | 118 | Horizon Pharma plc ($21,306) |
| 2017 | $18,787 | 124 | Horizon Pharma plc ($13,847) |
All Payment Transactions
1,035 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $30.01 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Travel and Lodging | Cash or cash equivalent | $51.19 | General |
| Category: Immunology | ||||||
| 12/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.39 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: Bone Health | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,475.00 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $31.16 | General |
| 11/25/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $127.13 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $34.53 | General |
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $40.32 | General |
| Category: Immunology | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: RESPIRATORY | ||||||
| 10/30/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $28.14 | General |
| 10/30/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $130.06 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $76.60 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/24/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Rheumatology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $75.17 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $32.15 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $20.46 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO | GlaxoSmithKline, LLC. | $1,399 | 14 |
| A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $554.90 | 2 |
| Cardiovascular disease, chronic kidney disease, pain, and psychological issues in patients with controlled vs. uncontrolled gout: a retrospective claims-based cohort analysis | Amgen Inc. | $220.83 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 863 | 262,760 | $7.0M | $1.6M |
| 2022 | 19 | 1,046 | 212,036 | $5.3M | $1.3M |
| 2021 | 17 | 851 | 177,158 | $4.6M | $1.3M |
| 2020 | 16 | 726 | 112,083 | $3.1M | $984,385 |
Total Patients
3,486
Total Services
764,037
Medicare Billing
$5.1M
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 66 | 232,840 | $4.7M | $899,642 | 19.3% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 12 | 6,175 | $617,500 | $208,202 | 33.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 21 | 18,725 | $936,250 | $197,054 | 21.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 66 | 1,168 | $233,600 | $90,403 | 38.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 73 | 465 | $186,000 | $64,911 | 34.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 280 | 458 | $107,630 | $50,546 | 47.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 20 | 2,220 | $111,000 | $40,597 | 36.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 69 | 69 | $31,050 | $9,818 | 31.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 76 | 96 | $22,560 | $7,504 | 33.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 149 | $29,800 | $4,361 | 14.6% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 12 | 81 | $8,100 | $3,191 | 39.4% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 18 | 28 | $6,840 | $2,759 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 29 | $4,205 | $2,193 | 52.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 46 | 107 | $5,350 | $1,502 | 28.1% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 33 | 43 | $2,150 | $401.05 | 18.7% |
| J1020 | Injection, methylprednisolone acetate, 20 mg | Office | 2023 | 14 | 18 | $540.00 | $91.05 | 16.9% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 11 | 89 | $1,150 | $75.99 | 6.6% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 52 | 187,600 | $3.8M | $832,945 | 22.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 19 | 19,950 | $997,500 | $233,473 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 329 | 649 | $152,515 | $68,083 | 44.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 17 | 1,740 | $87,000 | $28,283 | 32.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 53 | 181 | $72,400 | $25,521 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 113 | 113 | $50,850 | $15,867 | 31.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 85 | 923 | $46,150 | $12,758 | 27.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 36 | 169 | $67,600 | $11,711 | 17.3% |
About Dr. Suneet Grewal, M.D
Dr. Suneet Grewal, M.D is a Rheumatology healthcare provider based in West Hollywood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/28/2011. The National Provider Identifier (NPI) number assigned to this provider is 1811264476.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Suneet Grewal, M.D has received a total of $359,594 in payments from pharmaceutical and medical device companies, with $35,890 received in 2024. These payments were reported across 1,035 transactions from 34 companies. The most common payment nature is "Honoraria" ($182,534).
As a Medicare-enrolled provider, Grewal has provided services to 3,486 Medicare beneficiaries, totaling 764,037 services with total Medicare billing of $5.1M. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location West Hollywood, CA
- Active Since 11/28/2011
- Last Updated 11/28/2011
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1811264476
Products in Payments
- KRYSTEXXA (Biological) $165,811
- Cimzia (Drug) $61,950
- KRYSTEXXA (Drug) $34,676
- SIMPONI ARIA (Biological) $25,881
- TREMFYA (Drug) $14,613
- BENLYSTA (Biological) $12,022
- Humira (Biological) $8,155
- SAPHNELO (Biological) $6,438
- STELARA (Biological) $2,240
- COSENTYX (Biological) $1,593
- Enbrel (Biological) $1,211
- RAYOS (Drug) $508.57
- Otezla (Drug) $394.86
- RINVOQ (Biological) $370.68
- ORENCIA (Biological) $338.19
- Rituxan (Biological) $289.47
- XELJANZ (Drug) $276.60
- OFEV (Drug) $244.54
- EVENITY (Biological) $240.28
- TALTZ (Drug) $208.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in West Hollywood
Francesco Boin, M.d, M.D
Rheumatology — Payments: $30,902
Rheumatology $30,902
Dr. Karen Shainsky, D.o, D.O
Rheumatology — Payments: $25,036
Rheumatology $25,036
Patil Injean, Do, DO
Rheumatology — Payments: $125.00
Rheumatology $125.00
Dr. Jana Posalski, M.d, M.D
Rheumatology
Rheumatology
Dr. Judy Maddox, Do, DO
Rheumatology
Rheumatology